NCT01906632View on ClinicalTrials.gov

Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 30, 2022

Study Completion Date

June 30, 2023

Conditions
Malignant Tumor
Interventions
BIOLOGICAL

DC-CIK Immunotherapy

Trial Locations (1)

100038

Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital, Beijing

All Listed Sponsors
lead

Capital Medical University

OTHER

NCT01906632 - Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy | Biotech Hunter | Biotech Hunter